SCHEMBL3228639

SCHEMBL3228639

CCc1nc2c(c(=O)n(Cc3ccc(Cl)cc3)c(=O)n2CC(=O)c2ccccc2)n1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
HSD17B10 Q99714 2/20 0.48
MAPT P10636 3/20 0.47
ADORA2A P29274 2/20 0.47
ADORA2B P29275 2/20 0.47
HIF1A Q16665 2/20 0.47
LMNA P02545 2/20 0.47
ADORA1 P30542 2/20 0.47
HTT P42858 2/20 0.46
TSHR P16473 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.44
POLB P06746 1/20 0.44
AGTR1 P30556 1/20 0.44
USP2 O75604 1/20 0.44
CASP1 P29466 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235070 0.91 MAPT (0.44) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3110981 0.89 MAPT (0.48) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3229109 0.88 ADORA2A (0.59) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3267243 0.86 HTT (0.52) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3224112 0.86 MAPT (0.48) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3234639 0.85 MAPT (0.55) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL13940722 0.84 POLB (0.52) ALDH1A1NPSR1MAPTHIF1ALMNA
SCHEMBL3221667 0.84 MAPT (0.46) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3238173 0.83 MAPT (0.55) ALDH1A1NPSR1MAPTADORA2AADORA2B
SCHEMBL3236101 0.83 ADORA2A (0.51) ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US claimed
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 ALDH1A1 1248/4885NPSR1 47/4885HSD17B10 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.